{"name":"Immatics US, Inc.","slug":"immatics-us-inc","ticker":"","exchange":"","domain":"immaticsus.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"IMA101 product","genericName":"IMA101 product","slug":"ima101-product","indication":"Other","status":"phase_1"},{"name":"IMA203 Product","genericName":"IMA203 Product","slug":"ima203-product","indication":"Other","status":"phase_1"},{"name":"IMA201 Product","genericName":"IMA201 Product","slug":"ima201-product","indication":"Other","status":"phase_1"},{"name":"nivolumab plus relatlimab","genericName":"nivolumab plus relatlimab","slug":"nivolumab-plus-relatlimab","indication":"Malignant pleural mesothelioma","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"IMA203","genericName":"IMA203","slug":"ima203","indication":"PRAME-positive melanoma","status":"phase_3"},{"name":"paclitaxel plus carboplatin","genericName":"paclitaxel plus carboplatin","slug":"paclitaxel-plus-carboplatin","indication":"Non-small cell lung cancer","status":"phase_3"}]}],"pipeline":[{"name":"IMA101 product","genericName":"IMA101 product","slug":"ima101-product","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"IMA203","genericName":"IMA203","slug":"ima203","phase":"phase_3","mechanism":"IMA203 is a T-cell engager that redirects patient T cells to recognize and kill cancer cells expressing the PRAME antigen.","indications":["PRAME-positive melanoma","PRAME-positive solid tumors"],"catalyst":""},{"name":"IMA203 Product","genericName":"IMA203 Product","slug":"ima203-product","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"IMA201 Product","genericName":"IMA201 Product","slug":"ima201-product","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"nivolumab plus relatlimab","genericName":"nivolumab plus relatlimab","slug":"nivolumab-plus-relatlimab","phase":"phase_3","mechanism":"Nivolumab plus relatlimab is a combination immunotherapy that targets the PD-1/PD-L1 axis to enhance anti-tumor immune responses.","indications":["Malignant pleural mesothelioma"],"catalyst":""},{"name":"paclitaxel plus carboplatin","genericName":"paclitaxel plus carboplatin","slug":"paclitaxel-plus-carboplatin","phase":"phase_3","mechanism":"Paclitaxel works by inhibiting cell division, while carboplatin interferes with DNA repair, both leading to cell death in rapidly dividing cancer cells.","indications":["Non-small cell lung cancer","Ovarian cancer","Breast cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-15","type":"pipeline","source":"simplywall.st","summary":"Assessing Immatics (IMTX) Valuation After Strong One Year Return And High Price To Sales Ratio - simplywall.st","headline":"Assessing Immatics (IMTX) Valuation After Strong One Year Return And High Price To Sales Ratio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPTDcwc0YzQ0o1SDBocXhzbUFKMDdKQktrRmQyUXJ3d3RGV2Z4VURBbW02Z2ZhNlQ1dzRsXy1vTkJrWHZYMHBxWnljS21pVWdUQ0paT2dPQ19vQThKN1dZQnJLQXFRYlQ5OEhCalJKbWFyVkdLWmh2N0p3YUhhOUhZVHhBUHMwaFlJcWhHcnBGbDdHUmUtQWtrblEtRFM?oc=5","date":"2026-03-06","type":"trial","source":"openPR.com","summary":"TCR Therapy Clinical Trial Pipeline Accelerates as 50+ Pharma - openPR.com","headline":"TCR Therapy Clinical Trial Pipeline Accelerates as 50+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPUkxzanF3SU9MSUVhWVhPdFpoTEszMWVvazNUOHplazl1NnVHUlpWQmxCOUxGWG56VzFBNFVpTUs5SHFFbDMyRHItMmtnVTNpVHRQX29NTTZOZ2c3S1doWXNzTXBWNVJ0ZkZHWXVURU1sZkJvX19vMmpLdFYzbTdJUHlKWQ?oc=5","date":"2026-01-20","type":"pipeline","source":"Medical Marketing and Media","summary":"40 Under 40: Lauren Schroeder, Immatics - Medical Marketing and Media","headline":"40 Under 40: Lauren Schroeder, Immatics","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-05","type":"earnings","source":"simplywall.st","summary":"Revenues Not Telling The Story For Immatics N.V. (NASDAQ:IMTX) After Shares Rise 28% - simplywall.st","headline":"Revenues Not Telling The Story For Immatics N.V. (NASDAQ:IMTX) After Shares Rise 28%","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQRThoSE5oRWpsQzdDVEZrZEhHR0d0TnZwYXZNM3NhYkVzLVR4SWlYcXprQUVxd1EyTDdWSVljY2h1SGgyN0F4czFQbFBabk0wSUFDeWNPR2N6d2pUM3ZiVzJxbU11VXZpbENKbXZZVWtSV3o3clZZemFTb0JzTFljM2lkMDcyRXc?oc=5","date":"2025-12-01","type":"pipeline","source":"BioSpace","summary":"6 Companies Hanging On in Cell Therapy - BioSpace","headline":"6 Companies Hanging On in Cell Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxQT195Um84VEw5TDFnZ0x5N0VydUJ0aDNTVGF1SDVWdjh0bEFwbEtyZzM4R2ZEbENDdTVwQzJSV0ZrUU9JSlVZbTZ5TXlYd3NyYmpXT3pVMzdEUHRuTi1lYURucmpkR2M4bzJTeTFNU05iM3dIX0JNNzdoT1otUWVoT3VZamZrTzA5bmYxaUxmTEMxZVpuWm5aRFlVdmZWeXRxU2lWclBRLXg0eEZndGl6VkxBUGRYWjFHdHp0bU9jdnQ1SmpfLXlOd3dPTkhSMTJPRHdDZlpfMjdHQjNyR21Zd2pnU21aQTNOam1SZUw5ZkNyb19xOUMyc0pxRnl4Z2hnRHdLc19CTkdQSy1EYTdDTFRuYkZYRHE0S2tFYm1TMVI?oc=5","date":"2025-10-14","type":"trial","source":"globenewswire.com","summary":"Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma - globenewswire.com","headline":"Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPUVd3eHp6dEdjN3BZaTZiR3VpVktqVE9WZnNzb3B1ZEpMY3RDZ0pzV1FvSndvYXJxU2F6LXdQcXlmZHd5dEpuTUhjdG5pWHNwSU1iQVlJZDlsY3d3cmxqanozWVdfd0NYc19BaDZ3VlVkVXBjeXp2cjBIOWNqYVd2QVV5ZzhISHRaeUQyUlFrSjdHZUZMci1COWdOZ1FTdUFfQ2lFcXRZNjFHRTNfNG5IYW4taGVVcTdWVnRrYVZjbw?oc=5","date":"2025-10-03","type":"pipeline","source":"Eyes On Eyecare","summary":"Leadership watch: KALA BIO names new CEO, Aurion Biotech promotes execs - Eyes On Eyecare","headline":"Leadership watch: KALA BIO names new CEO, Aurion Biotech promotes execs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPQ2RrX2J1MGtKLVRrUVJKWEwwVVhEUTFLejRjNzg1LUtHTWZFX3RyWUl6WGNrSTN4Z3NILWJNLVlzMUVCQ1hNc25MaV8yV2tXZ3dPYnhJSXd4TERJVDg0NEZWTU9YVkNVNTN3U1JVeFlyazREU3VtVTI5QkM4eVQ3Y0pmNDRCZzB0TzdyRkVpTHpJVGxzMGwyWXNzZEVlRW9VbmMtcw?oc=5","date":"2025-04-30","type":"pipeline","source":"The Business Journals","summary":"Immatics US opens 100,000-square-foot Stafford cell-therapy manufacturing plant (PHOTOS) - The Business Journals","headline":"Immatics US opens 100,000-square-foot Stafford cell-therapy manufacturing plant (PHOTOS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5MNFhIY0I3aVBsT0U5MUpydG85SUI2MnFKc0FpRXV2SjQ1VktoY09Ec2NUMERUMW1aTjA1M3BBUmNBRnNST1J4eXRvbHZDb3ZnOFNEY3JTWXRjZGpkelVj?oc=5","date":"2025-04-09","type":"trial","source":"Nature","summary":"Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial | Nature Medicine - Nature","headline":"Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial | Nature Medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNMEpjdXpQczBMTnpRelNDQ0VNVmlrd25leldnUTVTRzJWZXFUQnFBZkJWTHBkVmFjeDZVa1dPYm1WcGJPczVBRFZCQjc2anprYjJEX2xHckxWZjlnRlJITVBtVVljTnNCVjhWZTg1ZWI5RFpOSXJOUmR3ZGVpQWRQRFlzUThJcUdlRGhFRkxucVUzUmZBbFE?oc=5","date":"2024-12-20","type":"patent","source":"drugdiscoverytrends.com","summary":"25 leaders in cell and gene therapy patents from 2020 to 2024 - drugdiscoverytrends.com","headline":"25 leaders in cell and gene therapy patents from 2020 to 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOakVpRTJfZEpUWFE5TElYYUFHMUk0WU85MUJrV0RSdmlGRDd1YlpRbXRqeF93MDFFTy01bHdCbDBxeE9DWWpYdVp2QnRNejF3dGM1aExyY21VTWs4TW1jQjBuNUJ6bjNuOHhfNTJNWEJlNzFldHIyaV82a0JaV2VEZHpOd2kzZlVIczk0?oc=5","date":"2024-07-17","type":"pipeline","source":"European Biotechnology Magazine","summary":"Immatics launches US$250m Nasdaq-IPO - European Biotechnology Magazine","headline":"Immatics launches US$250m Nasdaq-IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPUVU1T21SV0gzVE9rNnVEWVRYOVJFOWxsa2FEODktYjh3V0l6MWhnWUgweTJUX2FWaW1Bc1lDNmhNZnVzaGhfalVhUUYzQ3k5VjRoVXpNb3JHWHo4M0s1SC1lYjVINTllNEFBSkVVUFZ1SHJHVUFMT0ZLR3ZjSDZGcFBxTDhkajRqb2lGM1RCd2ZzX0Zab2VSZkhOUEFpNlhOS085Rm1QNzAzVFgyTmRvbEt2M0ZZVnp2?oc=5","date":"2023-09-11","type":"pipeline","source":"reuters.com","summary":"Moderna ties up with Immatics to boost cancer vaccine development - reuters.com","headline":"Moderna ties up with Immatics to boost cancer vaccine development","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_1":3,"phase_3":3},"enrichmentLevel":0,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}